Login
Companies $PRME
$4.23 +$0.04 (0.97%) After hours
Prime Medicine, Inc. logo

Prime Medicine, Inc.

primemedicine.com

What Do They Do?

Develops Prime Editing medicines for patients with genetic diseases, including liver and lung conditions and blood disorders, and works with partners on edited T-cell programs for cancer and immune diseases.

How Do They Make Money?

Partners pay Prime under research collaboration and licensing agreements through upfront fees, cost reimbursements, option and milestone payments; Prime earns revenue over the expected work period under each agreement.

FY2025 revenue

Who Are Their Customers?

Research and licensing partners work with Prime through agreements; its collaboration with Bristol-Myers Squibb applies Prime Editing to ex vivo T-cell engineering. Prime expects revenue primarily from current and future collaboration agreements.

Do Revenues Turn Into Profits?

No. It lost $201.1M in FY2025.

Operating income, FY2025
โˆ’4498% of revenue
โ–ผ โˆ’3% (Loss) vs FY2024 (โˆ’$202.5M, โˆ’6787%)
Net income, FY2025
โˆ’4342% of revenue
โ–ผ โˆ’3% (Loss) vs FY2024 (โˆ’$195.9M, โˆ’6567%)
Free cash flow, FY2025
โˆ’3607% of revenue
โ–ผ โˆ’28% (Loss) vs FY2024 (โˆ’$130.2M, โˆ’4363%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
โ–ฒ +244%
vs $1.2M in Q3 FY2025
Net income
โ–ฒ +23% (Loss)
vs โˆ’$50.6M in Q3 FY2025
  • Apr 7, 2026 Prime Medicine appointed Svetlana Makhni as CFO She became chief financial officer and principal financial officer effective April 16, 2026.

Narrower development focus The older report described programs spanning blood, liver, eye and ear diseases and several delivery methods; the latest centers internal development on liver-directed in vivo editing, while continuing cystic fibrosis research and partnered ex vivo T-cell work.

Who Do They Compete With?

Competes with CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Caribou Biosciences, Beam, Verve Therapeutics, Tessera Therapeutics, Metagenomi Therapeutics, Scribe Therapeutics, Arbor Biotechnologies, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Sarepta Therapeutics, Wave Life Sciences, Moderna, Ultragenyx, Genetix Biotherapeutics, 4D Molecular Therapeutics, Vertex Pharmaceuticals, and Arrowhead Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support